1. GLOBAL PHARMACEUTICAL MARKET
1. Growing at a CAGR of around 8%, the global pharmaceutical market is
forecasted to reach US$ 1043.4 Billion in 2012.
2. North America remains the largest pharmaceutical market constituting 42.8% of
the global sales in 2007. Growth in the region is however expected to slow down
in near future owing to patent expiration of key drugs and increased prevalence of
generics.
3. In Europe, growth in the top five markets is expected to remain sluggish in next
five years. Emerging markets in Central and Eastern Europe is however expected
to drive growth in future.
4. A large untapped population and strong economic growth in major countries is
“
“The global
pharmaceutical
market value is
expected to expand
expected to make Asia-Pacific the most lucrative pharmaceutical market in
future. over $1.1 trillion
5. Growth in the Latin American markets is expected to be strong with Brazil and USD by 2014,”
Mexico amongst the most emerging pharmaceutical markets in the world.
6. Dwindling drug pipelines and patent expiration of a number of blockbuster drugs
may challenge the growth of global pharmaceutical market in future.
”

3. Diabetes , is a group of metabolic diseases in which
a person has high blood sugar, either because the body
does
not produce enough insulin, or because cells do not
respond
to the insulin that is produced.
There are three main types of diabetes:
Type 1 diabetes: results from the body's failure to produce
insulin, and presently requires the person to inject insulin. {OR
insulin-dependent diabetes mellitus, (IDDM )} & juvenile
diabetes.)
Type 2 diabetes: results from insulin resistance, a condition in
which cells fail to use insulin properly, sometimes combined
with an absolute insulin deficiency. {OR non-insulin-dependent
diabetes mellitus, NIDDM)} & adult-onset diabetes.)
Gestational diabetes: is when pregnant women, who have
never had diabetes before, have a high blood glucose level
during pregnancy. It may precede development of type 2 DM.

4. GLOBAL DIABETES
POPULATION
Globally as of 2010 it is estimated that there are 285
million people diabetes with type 2 making up about 90%
of the cases.
• it is estimated that by 2030, this number will almost
double.
•It is more common (especially type 2) in the more
developed countries.
• it is expected that in Asia and Africa, where most
patients will probably be found by 2030.
•The increase in incidence of diabetes in developing
countries follows the trend of urbanization and lifestyle
changes, perhaps most importantly a "Western-style“
diet.

5. PREVALENCE OF DIABETES COUNTRY WISE

6. GLOBAL DIABETES MARKET
 The global market for products in the management of
diabetes currently stands at $41 billion and is on pace to
grow to over $114 billion by 2018.
 Oral anti-diabetics were the leading category of drugs
in 2010 and showed a growth rate of 6.3% from the total
global sales.
The total sales for insulin products increased significantly
as well.

7. Global Diabetes Market Trends & Future Forecast
USA controls more than 50% of the total Diabetes Drug market
share in 2009.
• Global Insulin Market is estimated to reach around US$ 17 Billion
by 2013.
• China will have the second highest Insulin market share by 2012
replacing Germany.
• DPP-IV Inhibitors is predicted to be more than US$ 5 Billion
market by 2015.
• LP-1 Agonists, market is forecasted to cross US$ 6 Billion mark
by 2015 .
• Novorapid is the blockbuster Insulin of Novo Nordisk it is
expected to cross US$ 3 Billion by 2015.

8. Global Diabetes Market Trends & Future Forecast
• Yet to launched Degludec and Degludec Plus is expected to be
blockbuster Insulin and cross US$ 4 Billion and US$ 6
Billion respectively by 2030.
• Januvia is proving a blockbuster of DPP – IV Inhibitors segment
expected to be more than US$ 4 Billion by 2017 .
•Last year launched Victoza and yet to be launched Exenatide
LAR is going to be blockbuster GLP-1 Agonists .
• China diabetes drug market has crossed the figure of Yuan 10
Billion by 2009.
• Japan Insulin market is expected to be more than US$ 1 Billion
by 2010.

9. Global DIABETES TOP PLAYERS

10. PRODUCTS STRONG IN DIABETES
MARKET
Anti-diabetic products include glucose meters, lancets, test strips,
continuous blood glucose meters, insulin, insulin pumps, syringes
and other insulin delivery devices and anti-diabetic drugs.
The bulk of product revenues come from three segments - test
strips, insulin and anti-diabetic drugs - which will remain the
largest sources of product revenues over the next ten years.
The most significant growth, however, will come from the nascent
segment of continuous blood glucose monitors, which provide
significantly added clinical benefit at only a modestly higher cost
compared to standard blood glucose meters.

11. NEW MOLECULES DEVELOPING FOR
DIABETES
University of Technology, Sydney. UTS researchers have
identified molecules secreted by a parasitic worm that prevent
the development of Type 1 diabetes in mice.
A commercial version of the product is currently being
developed for use in humans.
Researchers at the Stanford University School of Medicine
have identified a key molecular pathway responsible for the
natural decrease in the proliferation of insulin-producing cells
that occurs as a person ages. Artificially activating this
pathway, which is normally not functional in adults, may be a
new way to combat diabetes.

12. INDIAN DIABETES MARKET
With around 51 million diabetic patients, India promises to be
amongst the most lucrative diabetes markets in the world. In
2009, the total sales of insulin and non-insulin anti-diabetics
reached $424 million, according to the findings of a news report
added to the offering of Research and Markets.
REPORT HIGHLIGHTS
• A growing drug treated population coupled with the launch of
several new drugs will drive the Indian diabetes market to $1.4
billion by 2015.
• In 2009, the market for non-insulin anti-diabetics was worth $306
million. This represented a highly fragmented market with domestic
diabetes care firm USV being the leading player with a 14% share.
• USV’s Glycomet GP (glimepiride+metformin) was the leading
drug
in the non-insulin anti-diabetics market with sales worth nearly

13. INDIAN DIABETES MARKET
•The authors expect around 15 new drugs to be launched in the
non-insulin anti-diabetics market in the next five years. Seven of
them are expected to be in the DPP-IV inhibitor and GLP-1 agonist
classes.
• The insulin market was worth $117 million in 2009. US health care
major Abbott Laboratories was India's biggest player accounting
for 61% of the total sales.
• Sanofi-Aventis’ Lantus (insulin glargine) represented one of the
fastest growing drugs in the last five year and registered sales worth
nearly $11 million in 2009
• The total number of diabetes patients in India is expected to reach
87 million by 2030. Around 56% of these patients will be from
urban regions of the country.

14. INDIAN DIABETES TOP PLAYERS

15. THE INDIAN MARKET
OPPORTUNITY
•World’s largest diabetes patient pool
•Success of newly launched drugs
•Increasing diagnosis and drug treated rates
•A rapidly growing market
In 2010, total sales of insulin and oral anti-diabetics in India
reached INR 28 billion, of which, the market for oral anti-
diabetics was worth INR 17 billion**. With the number of
diabetics increasing, the market, over the next five years, will
be driven by the strong uptake of insulin analogs.
Januvia is proving a blockbuster of DPP – IV Inhibitors segment
expected to be more than US$ 4 Billion by 2017 (GLOBALLY)